麻豆国产精品一二三在线观-麻豆国产精品一二三在线观看-麻豆国产精品一区二区-麻豆国产精品永久免费视频-麻豆国产巨作av剧情-麻豆国产蜜桃臀视频在线观看

印度Nicholas Piramal India Limited 
Nicholas Piramal印度有限公司（印度Mumbia）的委托生產(chǎn)部門(mén)NPIL Pharma公司在2005年收購(gòu)了Avecia制藥公司，正在試圖發(fā)展成為最大的三家委托合成公司之一。

對(duì)于NPIL Pharma 公司來(lái)說(shuō)2006年最優(yōu)先要走做的事情是在完成早先進(jìn)行的收購(gòu)后將Avecia公司的委托化學(xué)合成和藥物生產(chǎn)服務(wù)業(yè)務(wù)整合進(jìn)來(lái)。通過(guò)這次收購(gòu)，NPIL Pharma公司獲得三個(gè)商業(yè)部門(mén)：1、早期交付小組，位于英國(guó)Huddersfield，致力于I期和II期臨床試驗(yàn)產(chǎn)品的委托合成；2、藥物產(chǎn)品部門(mén)，位于英國(guó)的Huddersfield和Billingham，致力于擴(kuò)大并生產(chǎn)后期中間體和API，用于III期臨床試驗(yàn)和產(chǎn)品上市銷售；3、高效底物部門(mén)，位于蘇格蘭的Grangemouth，致力于研發(fā)、擴(kuò)大和生產(chǎn)高效前列腺素和細(xì)胞毒API。NPIL Pharma做為收購(gòu)Avecia公司的一部分，公司還擁有了Avecia公司的子公司Torcan Chemical公司，該公司位于加拿大安大略Aurora，致力于臨床前和早期臨床試驗(yàn)產(chǎn)品開(kāi)發(fā)。同時(shí)，公司還獲得了Reaxa公司（英國(guó)曼徹斯特，）25％的股票，該公司致力于催化技術(shù)，也創(chuàng)立于Avecia公司。

Avecia公司的資產(chǎn)將被整合進(jìn)NPIL Pharma公司的資產(chǎn)中，NPIL Pharma公司在印度擁有4個(gè)生產(chǎn)部門(mén)，包括Mumbai和Chennai的研發(fā)實(shí)驗(yàn)室，Chennai的GMP車(chē)間，Hyderabad的大規(guī)模車(chē)間。

收購(gòu)Avecia公司是NPIL公司在委托合成領(lǐng)域內(nèi)的第一個(gè)收購(gòu)行為，NPIL Pharma公司現(xiàn)在正在向全球大型委托合成企業(yè)方向邁出一大步，成為少數(shù)幾個(gè)將API/中間體開(kāi)發(fā)和生產(chǎn)整合到一起形成最終劑型藥物的委托生產(chǎn)企業(yè)中的一個(gè)。

NPIL Pharma公司是Nicholas Piraml印度有限公司的一部分，Nicholas Piraml印度有限公司是印度第四大制藥保健公司，2005年收入達(dá)到2億9100萬(wàn)美元。

Nicholas Piramal India Limited is one of India's largest companies with an unmatched record of managing JVs/Alliances/Partnerships, and a proven commitment to IPR. With strong brand management and sales capabilities, a US FDA site-approved plant for on-and-off patent APIs and Intermediates, Basic Research, Process Innovation, Custom Chemical Synthesis, Formulations R&D, NDDS, and a world-class, accredited Clinical Research Organisation, NPIL is poised to emerge as India's pharma powerhouse.

With growth fuelled through a strategy of partnerships, quality acquisitions, brand building, focused selling and manufacturing, NPIL's consolidated net sales turnover was US$ 313 million (INR 14.1 billion) in 2005-06 (April to March)".

NPIL has emerged among the leaders in Indian pharma with a unique mix of inorganic and organic growth fuelled through a strategy of acquisitions, brand building and focused selling, and manufacturing. The company has one of the widest product portfolios in India, spanning nine key therapeutic areas, including the Cardio-vascular, Neuro-psychiatry, Oncology, Diabetes Management, Respiratory, Anti-infectives, Gastro-intestinals, Dermatology and NSAIDS.

The company was formed when the Piramal Group acquired Nicholas Laboratories, a small formulations company in 1988 from Sara Lee. It has followed a multi-pronged strategy to integrate and maximize synergies with the planned acquisitions and develop and consolidate its major strength in marketing to therapeutic niches.

Managed by a team of highly proficient industry professionals, NPIL's key strengths come from its strong brand building, selling and distribution, manufacturing and alliance/partnership management skills. The last, especially, are quite unique in the Indian context - few Indian Pharmaceutical have exhibited such a strong and consistent record in successfully and ethically managing JVs/Alliances and Partnerships as NPIL has.

Its policy of respecting IPR and managing partnerships, in keeping with both the letter and the spirit of written agreements, has been widely respected and commended by its partners.

NPIL is the flagship company of the Rs. 2500 crore (US $ 550 million) Piramal Enterprises (PEL), one of India's largest diversified business houses.